Capital Expenditures for DexCom (DXCM)
According to DexCom's latest reported financial statements, the company's current capital expenditures (TTM) is $363.50M USD. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
DXCM
Currently viewingCapital ExpendituresSwitch metric
Latest period
$363.50M
YoY change
+1.3%
5Y CAGR
+12.8%
Peak year (2021)
$389.20M
Cumulative capital expenditures
$2.38B
CapEx history chart for DexCom (DXCM) from 2003 to 2025
CapEx history table for DexCom (DXCM) from 2003 to 2025
| Fiscal year | Period ended | Reported | Capital Expenditures | YoY |
|---|---|---|---|---|
| 2025 | $363.50M | +1.3% | ||
| 2024 | $358.80M | +51.6% | ||
| 2023 | $236.60M | -35.1% | ||
| 2022 | $364.80M | -6.3% | ||
| 2021 | $389.20M | +95.6% | ||
| 2020 | $199.00M | +10.6% | ||
| 2019 | $180.00M | +168.3% | ||
| 2018 | $67.10M | +1.7% | ||
| 2017 | $66.00M | +18.5% | ||
| 2016 | $55.70M | +67.3% | ||
| 2015 | $33.30M | +105.6% | ||
| 2014 | $16.20M | +105.1% | ||
| 2013 | $7.90M | -16.8% | ||
| 2012 | $9.50M | +18.7% | ||
| 2011 | $8.01M | +16.7% | ||
| 2010 | $6.86M | +129.3% | ||
| 2009 | $2.99M | +20.1% | ||
| 2008 | $2.49M | -27.6% | ||
| 2007 | $3.44M | +2.7% | ||
| 2006 | $3.35M | -28.3% | ||
| 2005 | $4.68M | +166.1% | ||
| 2004 | $1.76M | +330.1% | ||
| 2003 | $408,609 | — |
CapEx values are taken from DexCom's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, DexCom (DXCM) capital expenditures totalled $363.50M – edged up 1.3% year-over-year.
DexCom capital expenditures compound annual growth for the 2020–2025 (5 years) window is +12.8%, sustaining 2 straight years of year-over-year growth.
DexCom capital expenditures peaked at $389.20M in 2021; the latest annual figure is $363.50M in 2025 (6.6% below peak).
$389.20M stands as the all-time-high annual capital expenditures, posted in 2021, against a low of $408,609 during 2003.
DexCom (DXCM) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $3.87B.
DexCom Capital Expenditures by Year
DexCom Capital Expenditures 2025: $363.50M
DexCom capital expenditures in 2025 was $363.50M, edged up 1.3% from 2024.
DexCom Capital Expenditures 2024: $358.80M
DexCom capital expenditures in 2024 was $358.80M, surged 51.6% from 2023.
DexCom Capital Expenditures 2023: $236.60M
DexCom capital expenditures in 2023 was $236.60M, plunged 35.1% below 2022.
DexCom Capital Expenditures 2022: $364.80M
DexCom capital expenditures in 2022 was $364.80M, declined 6.3% below 2021.
DexCom Capital Expenditures 2021: $389.20M
DexCom capital expenditures in 2021 was $389.20M.
See more financial history for DexCom (DXCM).
Sector peers — CapEx
Companies in the same sector as DexCom, ranked by their latest capital expenditures.
| Company | Capital Expenditures | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $90.11B | Healthcare |
| Eli Lilly and Company (LLY) | $7.84B | Healthcare |
| Johnson & Johnson (JNJ) | $4.83B | Healthcare |
| Merck & Co., Inc. (MRK) | $4.11B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $3.62B | Healthcare |
| AstraZeneca PLC (AZN) | $2.81B | Healthcare |
| Amgen Inc. (AMGN) | $1.86B | Healthcare |
| AbbVie Inc. (ABBV) | $1.21B | Healthcare |
Frequently asked questions
What is DexCom's capital expenditures?
- Latest reported capital expenditures for DexCom (DXCM) is $363.50M (period ending December 31, 2025).
How has DexCom capital expenditures changed year-over-year?
- DexCom (DXCM) capital expenditures changed +1.3% year-over-year on the latest annual filing.
What is the long-term growth rate of DexCom capital expenditures?
- DexCom (DXCM) capital expenditures compound annual growth rate is +12.8% over the most recent 5 years available.
When did DexCom capital expenditures hit its highest annual value?
- DexCom capital expenditures reached its highest annual value of $389.20M in 2021.
What was DexCom capital expenditures in 2024?
- DexCom (DXCM) capital expenditures in 2024 was $358.80M.
What was DexCom capital expenditures in 2025?
- DexCom (DXCM) capital expenditures in 2025 was $363.50M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
DXCM Overview
Company profile, financial tools, and key metrics
DXCM Revenue Counter
Earns $147.83 every second. See per minute, hour, and day.
DXCM Earnings Counter
Earns $26.52 per second net profit. See per minute, hour, and day.
DXCM Economic Scale
Exceeds Suriname's GDP. Compare with world economies.
DXCM What If Invested
What if you had invested $1,000? See historical returns from any date.
DXCM How It Makes Money
Discover visual breakdown of $4.66B in revenue — where it comes from and where it goes.
DXCM Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DXCM Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DXCM Daily Price Character
Explosive · 49.4% historical win rate (green days). Streaks & record days.
DXCM Buybacks
1.95% TTM buyback yield. Shareholder yield & SBC comparison.
DXCM Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.